Navigation Links
Licensing Agreement for Pharmaceutical Disposal Technology Between Teikoku Pharma USA, Inc. and Verde Environmental Technologies Inc.
Date:9/14/2011

SAN JOSE, Calif., Sept. 14, 2011 /PRNewswire/ -- Teikoku Pharma USA, Inc., ("TPU") is pleased to announce an exclusive license agreement with Verde Environmental Technologies Inc. ("Verde"), a company aimed at developing environmentally responsible solutions for pharmaceutical disposal.  Verde is a privately held company, founded by former executives of TPU and Travanti Pharma, Inc.

Verde obtained rights to develop products, which are designed to adsorb and inactivate the active ingredients in pills, tablets, capsules and topical patches, in a convenient and environmentally responsible manner, based on patented technology developed and owned by TPU.  

"We are very pleased that these new product ideas that were generated from our research led to this important new development, stated TPU CEO, Masahisa Kitagawa.  TPU located in San Jose, California is the US operations of Teikoku Seiyaku Co., Ltd., one of the world's largest manufacturers of medicated patches based in Japan, and its product, Lidoderm, is a leading global brand.

"The products being developed by Verde will address the growing issue of pharmaceutical contamination of groundwater supplies.  By providing an effective means of adsorbing the active ingredients, this will help keep waste pharmaceuticals from appearing in the water supply," stated Verde Chairman and CEO, Dr. Andrew Korey.  "In addition, these developments will provide anti-abuse features, and improved safety, by diminishing the risk of accidental poisoning from active pharmaceuticals disposed in trash."

About Teikoku

Teikoku Pharma USA Inc., a wholly-owned subsidiary of Teikoku Seiyaku Inc. of Japan, is a specialty pharmaceutical company that develops, and manufactures enhanced pharmaceutical products based on its transdermal drug delivery technologies. Teikoku focuses its efforts in two therapeutic areas; Pain Management and CNS. Teikoku's main product is Lidoderm® (Lidocaine 5% Patch) for PHN, in collaboration with Endo Pharmaceuticals in the US, Grunenthal GmbH in Europe, Mundipharma in South East Asia and SK Pharma for Korea.

For more information about Teikoku Pharma USA, Inc. please visit http://www.teikokuusa.com

About Verde

Verde Environmental Technologies Inc.,  is a company aimed at developing environmentally responsible solutions for the growing issues related to pharmaceutical disposal.  Products for pharmaceutical manufacturers, pharmacies, and consumers will incorporate carbon adsorptive technologies to inactivate residual active pharmaceutical ingredients in tablets, capsules, patches, etc., and make them safe for disposal in an environmentally responsible manner. Verde operations are based in Minnesota and California.

For more information about Verde environmental Technologies, Inc. please visit http://www.verdeenvirotech.com


'/>"/>
SOURCE Teikoku Pharma USA, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Beckman Coulter Announces Licensing Agreements for Molecular Tests with National University of Ireland, Galway
2. Lilly and Transition Therapeutics Announce Licensing and Collaboration Agreement
3. Orion Genomics Gains Exclusive Worldwide Rights to the IGF2 Gene for Colorectal Cancer Risk Testing Through Licensing Agreement With Johns Hopkins University
4. Lilly and TransPharma Medical Announce Licensing and Development Agreement
5. Genzyme and Isis Complete Licensing of Mipomersen
6. MabVax Therapeutics Closes Two Licensing Agreements With Sloan-Kettering Institute for Cancer Research
7. Lilly and Deciphera Pharmaceuticals Announce Licensing and Collaboration Agreement
8. CEL-SCI Announces Expansion of Exclusive Licensing Agreement for Cancer Drug Multikine
9. Ipsogen Expands its US Market Presence Through Licensing Agreement With ARUP Laboratories for the Commercialization of JAK2 Molecular Diagnostic Assays
10. Ironwood Announces Linaclotide European Licensing Agreement with Almirall
11. Addrenex Pharmaceuticals Expands Product Pipeline by Licensing New Drug to Treat Narcolepsy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2017)... , July 6, 2017 ThriveRx, the nutrition division of ... their families to thrive on nutrition support. To celebrate its ... new site has a fresh new look with improved organization to create ... ... ...
(Date:7/5/2017)... Oramed Pharmaceuticals Inc. (NASDAQ: ... clinical-stage pharmaceutical company focused on the development of oral drug ... the Israel Securities Authority to dual-list its common stock on ... commence trading on the TASE on July 12, 2017 under ... the Company, it is expected that Oramed will be included ...
(Date:7/5/2017)... , July 5, 2017   BioLife Solutions ... developer, manufacturer and marketer of proprietary clinical grade cell ... freeze media ("BioLife"), today announced that it has ... debt holder and largest shareholder, to modify its existing ... Pursuant to the modification, WAVI agreed to exchange its ...
Breaking Medicine Technology:
(Date:7/23/2017)... ... , ... Scientists from the University of Exeter reported this month ... equivalent to a medium-paced run for pre-menopausal women, or a slow jog for post-menopausal ... spine care, I understand the importance exercise can play on improving bone health. Although ...
(Date:7/23/2017)... Fla. (PRWEB) , ... July 23, 2017 , ... ... M.D., has joined Florida Pain Relief Group – Melbourne, a practice owned by ... board certification in interventional pain management, Dr. Stern also is certified in pediatrics, ...
(Date:7/22/2017)... ... July 22, 2017 , ... The arthroscopic superior capsule ... opportunity to return to sports and jobs that require heavy physical work, as ... Annual Meeting in Toronto, Ontario, Canada. , “We studied 100 patients ...
(Date:7/21/2017)... Orange Park, FL (PRWEB) , ... July 21, ... ... that provides insurance management assistance and financial planning services to families and business ... in a charity event that promises to provide support to area adults with ...
(Date:7/21/2017)... ... , ... Hospital M&A activity slowed in the second quarter of 2017, according ... to 23 in the second quarter, up 15% from the 20 publicly announced acquisitions ... in the year-ago second quarter. Only four of the transactions disclosed a purchase price ...
Breaking Medicine News(10 mins):